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The success of coronary artery bypass grafting is lim-ited by poor long-term graft patency. Despite thesuperior patency of arterial grafts, saphenous veinremains the most commonly used conduit for coro-
nary artery bypass because of its predictable handling qualities
and ready availability.1 Over 40% of vein grafts are thrombosed
at 10 years postoperatively,2 largely as a consequence of vein
graft disease that is characterized by neointima formation,
atherosclerosis, and plaque rupture. Graft failure results in
recurrent angina, myocardial infarction, or death and leads to
repeat revascularization procedures with their associated mor-
bidity and costs. To date, with the exception of aggressive lipid
lowering, no therapy has been shown to improve long-term vein
graft patency in clinical studies. In porcine saphenous vein to
carotid artery interposition graft, placement of a loose-fitting
external macroporous Dacron sheath inhibits vein graft disease
in the long term.3,4 The aim of this phase I randomized pilot
study was to evaluate the effects of placement of the external
Dacron stent, or Extent (Vascutek Ltd, Inchinnan, Scotland), on
vein graft disease in patients undergoing elective coronary
artery bypass grafting.
Materials and Methods
Between March and September 2005, 20 patients undergoing
isolated on-pump coronary artery bypass grafting, and who had
given informed consent, were randomized to have an Extent
placed to either a right coronary system graft or left coronary
system target graft. The Extent is an incomplete tube of knitted
polyester reinforced with polytetrafluoroethylene ribs at ap-
proximately 1-cm intervals to maintain rigidity (Figure 1). The
edges of the incomplete tube form a flange. The stent was so
designed to maintain the circular cross section of the graft and
to facilitate placement after completion of both distal and
proximal anastomoses, with the flange preventing migration or
kinking of the vein graft through the side of the graft. Two graft
sizes were used, 8 mm and 6 mm. Graft sizing was intended to
be nonrestrictive with up to 1-mm clearance around the circum-
ference of the vein graft. Patients were eligible if they were to
receive a reversed long saphenous vein graft to both the right
and left coronary systems in addition to a pedicled left internal
thoracic artery graft to the left anterior descending coronary
artery. The Extent was placed on the vein graft after the
proximal and distal anastomoses had been completed and pro-
tamine administered. Where possible, the proximal and distal
ends of the graft were sutured to the epicardium distally and to
the aortic adventitia to prevent migration; however, in 9 of the
grafts, postdeployment trimming of the proximal or distal anas-
tomoses to optimize the graft lie prevented this. The flange was
allowed to lie as appeared optimal to the graft curvature around
the heart. The study had received local ethical review board
approval, and all patients gave informed consent to the proce-
dure. The primary end point of the study was a 20% reduction
of wall thickness as assessed by intravascular ultrasound at 6
months after surgery relative to the untreated contralateral vein
graft.
Results
Key demographic, operative, and postoperative data are listed in
Table 1. One patient randomized to a left-sided Extent had the
stent placed on a graft to the posterior descending, inasmuch as the
left-sided target was heavily calcified. Two patients refused to
attend for follow-up and 1 subsequently reported an allergic reac-
tion to iodinated contrast. At follow-up angiography (9 conven-
tional, 8 computed tomographic) all 17 Extent grafts were throm-
bosed. All left internal thoracic artery and non-Extent vein grafts
were patent.
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Figure 1. Extent, a macroporous Dacron sheath reinforced with
polytetrafluoroethylene ribs. The flange permits placement after
completion of both anastomoses.
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Discussion
The most likely explanation for the universal thrombosis of Extent
vein grafts in this phase 1 study is that stent rigidity, oversizing, or
the incomplete tube design resulted in grafts kinking, either at the
anastomoses or within the middle part of the graft. This could have
occurred as a consequence of stent or graft movement on chest
closure or patient repositioning or at some later time. The potential
for this to occur was not foreseen. Preclinical studies had been
performed in the end to end or end to side porcine carotid artery
interposition model where the vessels are shorter and the potential
for graft movement and kinking is less, although the degree of
graft oversizing was similar.
Despite the poor results of the Extent study, the dramatic and
sustained effectiveness of external sheaths in experimental studies
suggests that continued research is warranted. One alternative is a
nonrestrictive, flexible, biodegradeable, macroporous polyglactin
(Vicryl; Ethicon, Inc, Somerville, NJ) external sheath. These fea-
tures overcome many of the limitations of the rigid Dacron stent
and have also demonstrated long-term inhibition of vein graft
disease in the porcine model.5
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TABLE 1. Extent study demographic, operative, and outcome data
Study
No. Sex
Age
(y) Randomization
Extented
vein graft
target
Proximal
coronary
stenosis
Extent
size
(mm)
Non-Extent
vein grafts
Postop
complication
Follow-up
(mo)
Patent
grafts
Occluded
grafts
Symptoms/
repeat
revascularization
1 M 76 L Int 75%–90% 6 PDA 6 PDA Int
2 M 72 L PDA Occluded 8 OM1 OM1 PDA
3 M 73 L Int 75% 6 PDA,
OM2
6 PDA,
OM2
Int
4 M 68 L Int 75%–90% 8 PDA AF, LRTI 8 PDA Int
5 M 62 R PDA 90% 8 Int, OM1 Int, OM1 PDA
6 M 76 R PDA 75%–90% 6 OM1 19 OM1 PDA
7 M 66 R PDA 75% 8 OM1 AF 19 OM1 PDA
8 M 73 R PDA 90% 8 OM1 AF 6 OM1 PDA PCI
9 M 66 L Int 75% 8 PDA, D1 AF, heart block 7 PDA, D1 Int
10 M 67 L OM1 Occluded 8 PDA 18 PDA OM1 PCI
11 M 72 L Int 75%–90% 8 PDA 16 PDA Int
12 M 76 R PDA 90% 8 OM1 16 OM1 PDA PCI
13 M 71 R PDA 75% 8 OM1 AF 6 OM1 PDA
14 F 72 L OM1 90% 8 PDA 8 PDA OM1
15 M 70 L OM1 90% 6 PDA LCO,
tracheostomy
17 PDA OM1
16 F 69 R PDA 90% 6 PDA, D1 18 PDA, D1 PDA
17 M 75 R PDA 75%–90% 6 OM1, D1 AF, LRTI 17 OM1, D1 PDA
18 M 66 L Int 75% 6 PDA AF, LRTI 7 PDA Int
19 M 70 R PLV 75%–90% 8 PDA PDA PLV
20 M 63 R PDA Occluded 8 OM1 AF 17 OM1
M, Male; F, female; L, left; R, right; Int, intermediate artery; PDA, posterior descending artery; OM, obtuse marginal; D, diagonal; AF, atrial fibrillation; PLV,
posterior left ventricular; LRTI, lower respiratory tract infection; LCO, low cardiac output; PCI, percutaneous coronary intervention.
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